S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Smith & Nephew Stock Forecast, Price & News

-0.38 (-1.03 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume157,704 shs
Average Volume513,923 shs
Market Capitalization$16.05 billion
P/E Ratio28.31
Dividend Yield2.44%
30 days | 90 days | 365 days | Advanced Chart
Receive SNN News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Smith & Nephew logo

About Smith & Nephew

Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.39 out of 5 stars

Medical Sector

179th out of 1,351 stocks

Surgical Appliances & Supplies Industry

6th out of 26 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Smith & Nephew (NYSE:SNN) Frequently Asked Questions

Is Smith & Nephew a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Smith & Nephew stock.
View analyst ratings for Smith & Nephew
or view top-rated stocks.

What stocks does MarketBeat like better than Smith & Nephew?

Wall Street analysts have given Smith & Nephew a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Smith & Nephew wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Smith & Nephew?

Smith & Nephew saw a increase in short interest in August. As of August 13th, there was short interest totaling 883,900 shares, an increase of 45.6% from the July 29th total of 607,100 shares. Based on an average daily volume of 543,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.2% of the shares of the company are short sold.
View Smith & Nephew's Short Interest

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) released its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $0.59.
View Smith & Nephew's earnings history

How has Smith & Nephew's stock price been impacted by COVID-19 (Coronavirus)?

Smith & Nephew's stock was trading at $38.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNN stock has decreased by 5.7% and is now trading at $36.52.
View which stocks have been most impacted by COVID-19

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a semi-annual dividend on Friday, August 13th. Stockholders of record on Friday, October 1st will be paid a dividend of $0.288 per share on Wednesday, October 27th. This represents a yield of 1.9%. The ex-dividend date of this dividend is Thursday, September 30th.
View Smith & Nephew's dividend history

Is Smith & Nephew a good dividend stock?

Smith & Nephew pays an annual dividend of $0.90 per share and currently has a dividend yield of 2.44%. The dividend payout ratio of Smith & Nephew is 69.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 43.48% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.
View Smith & Nephew's dividend history.

What price target have analysts set for SNN?

8 equities research analysts have issued 1 year price targets for Smith & Nephew's shares. Their forecasts range from $46.50 to $55.00. On average, they expect Smith & Nephew's share price to reach $50.75 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price.
View analysts' price targets for Smith & Nephew
or view top-rated stocks among Wall Street analysts.

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the following people:
  • Roland D. Diggelmann, Chief Executive Officer & Non-Executive Director
  • Mark Gladwell, President-Global Operations & Business Services
  • Anne-Francoise Nesmes, Chief Financial Officer & Executive Director
  • Vasant Padmanabhan, President-Research & Development
  • Catheryn O'Rourke, Chief Legal & Compliance Officer

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by many different retail and institutional investors. Top institutional shareholders include Nuance Investments LLC (1.82%), Bank of Montreal Can (0.66%), Cambiar Investors LLC (0.40%), Bank of America Corp DE (0.28%), Bank of America Corp DE (0.28%) and Royal Bank of Canada (0.23%).

Which institutional investors are selling Smith & Nephew stock?

SNN stock was sold by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Northern Trust Corp, Envestnet Asset Management Inc., CIBC Private Wealth Group LLC, Citigroup Inc., Cambiar Investors LLC, Natixis Advisors L.P., and Wells Fargo & Company MN.

Which institutional investors are buying Smith & Nephew stock?

SNN stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Credit Suisse AG, Amundi, Marshall Wace LLP, Marshall Wace LLP, StoneX Group Inc., Nuance Investments LLC, and FMR LLC.

How do I buy shares of Smith & Nephew?

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $36.52.

How much money does Smith & Nephew make?

Smith & Nephew has a market capitalization of $16.05 billion and generates $4.56 billion in revenue each year. The medical equipment provider earns $448 million in net income (profit) each year or $1.29 on an earnings per share basis.

How many employees does Smith & Nephew have?

Smith & Nephew employs 18,000 workers across the globe.

When was Smith & Nephew founded?

Smith & Nephew was founded in 1856.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is www.smith-nephew.com.

Where are Smith & Nephew's headquarters?

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider can be reached via phone at 441923477100 or via email at [email protected].

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.